Vaccines (Sep 2023)

Vaccination in the Era of Immunosuppression

  • Fatima Alnaimat,
  • Jaleel Jerry G. Sweis,
  • Jacqueline Jansz,
  • Zeel Modi,
  • Supritha Prasad,
  • Ayman AbuHelal,
  • Christen Vagts,
  • Hali A. Hanson,
  • Christian Ascoli,
  • Richard M. Novak,
  • Ilias C. Papanikolaou,
  • Israel Rubinstein,
  • Nadera Sweiss

DOI
https://doi.org/10.3390/vaccines11091446
Journal volume & issue
Vol. 11, no. 9
p. 1446

Abstract

Read online

Patients with autoimmune inflammatory rheumatic diseases (AIIRDs) are at increased risk for severe infections. Vaccine responses and safety profiles may differ between AIIRD patients and the general population. While patients with autoimmune inflammatory rheumatic diseases (AIIRDs) often experience diminished humoral responses and reduced vaccine efficacy, factors such as the type of immunosuppressant medications used and the specific vaccine employed contribute to these outcomes. Notably, individuals undergoing B cell depletion therapy tend to have poor vaccine immunogenicity. However, despite these considerations, vaccine responses are generally considered clinically sufficient. Ideally, immunosuppressed AIIRD patients should receive vaccinations at least two weeks before commencing immunosuppressive treatment. However, it is common for many patients to already be on immunosuppressants during the immunization process. Vaccination rarely triggers flares in AIIRDs; if flares occur, they are typically mild. Despite the heightened infection risk, including COVID-19, among AIIRD patients with rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, and other diseases on immunosuppressants, the vaccination rates remain suboptimal. The future directions of vaccination in the era of immunosuppression will likely involve customized vaccines with enhanced adjuvants and alternative delivery methods. By addressing the unique challenges faced by immunosuppressed individuals, we may improve vaccine efficacy, reduce the risk of infections, and ultimately enhance the health outcomes. Additionally, clinical trials to evaluate the safety and efficacy of temporarily discontinuing immunosuppressants during vaccination in various AIIRDs are crucial.

Keywords